Validating cancer drug targets
- 24 May 2006
- journal article
- review article
- Published by Springer Nature in Nature
- Vol. 441 (7092) , 451-456
- https://doi.org/10.1038/nature04873
Abstract
A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as ‘validated’ before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.Keywords
This publication has 49 references indexed in Scilit:
- Molecular Determinants of the Response of Glioblastomas to EGFR Kinase InhibitorsNew England Journal of Medicine, 2005
- Fine allelotyping ofErbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor lociGenes, Chromosomes and Cancer, 2005
- The Concept of Synthetic Lethality in the Context of Anticancer TherapyNature Reviews Cancer, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor BiologyJournal of Clinical Oncology, 2005
- Cancer drug discovery through collaborationNature Reviews Drug Discovery, 2005
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Mutations of the BRAF gene in human cancerNature, 2002